Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in fellow eyes Maintenance of vision and anatomical improvements in study eye and fellow eye of patients previously treated First-in-class dendrimer nanomedicine that treats both eyes simultaneously with … Read more